Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder
characterized by usually progressive development of airflow obstruction that is not fully …

Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …

Background The bronchodilator response to short-acting β 2-agonist and short-acting
muscarinic antagonist monotherapies varies on a day-to-day basis within individual patients …

Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Chronic obstructive pulmonary disease (COPD) is associated with high morbidity and
mortality. COPD is typified by persistent, progressive airflow limitation and a range of …

This retrospective analysis of data from two multi-center, randomized, double-blind, parallel
group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50mcg …

PURPOSE: Current treatment guidelines for patients with moderate or severe COPD
recommend combination therapy with 2 or more long-acting bronchodilators with different …

PURPOSE: With the burden of COPD increasing, new treatment strategies to optimize
pharmacotherapy include combination therapies with complementary modes of action. This …

The most recent guidelines define COPD in a multidimensional way, nevertheless the
diagnosis is still linked to the limitation of airflow, usually measured by the reduction in the …